Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2012-06-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm300579zPMID 22708876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.

  2012cited by this paper
• A survey of small molecule glucagon receptor antagonists from recent patents (2006 – 2010)

  2011cited by this paper
• Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

  2011cited by this paper
• Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice

  2011cited by this paper
• Catalytic enantioselective hydrogenation of N-alkoxycarbonyl hydrazones: a practical synthesis of chiral hydrazines.

  2010cited by this paper
• C-H bonds as ubiquitous functionality: a general approach to complex arylated pyrazoles via sequential regioselective C-arylation and N-alkylation enabled by SEM-group transposition.

  2009cited by this paper
• Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.

  2009cited by this paper
• Nitrogen's reactivity of various 3-alkoxypyrazoles

  2009cited by this paper
• Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

  2008cited by this paper
• Discovery of potent, orally active benzimidazole glucagon receptor antagonists.

  2008cited by this paper
• Glucagon Receptor Antagonists for Type II Diabetes

  2008cited by this paper
• New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists

  2007cited by this paper
• A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog

  2007cited by this paper
• Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.

  2007cited by this paper
• New beta-alanine derivatives are orally available glucagon receptor antagonists.

  2007cited by this paper
• Glucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired β-Cell Function

  2006cited by this paper
• Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor.

  2006cited by this paper
• Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice

  2006cited by this paper
• Type 2 diabetes: principles of pathogenesis and therapy

  2005cited by this paper
• Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.

  2005cited by this paper
• Progress towards glucagon receptor antagonist therapy for Type 2 diabetes

  2005cited by this paper
• Glucagon as a target for the treatment of Type 2 diabetes

  2005cited by this paper
• A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

  2004cited by this paper
• Biaryl amide glucagon receptor antagonists.

  2004cited by this paper
• Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

  2004cited by this paper
• Role of the glucagon receptor in glucose homeostasis: a therapeutic target to improve glycemic control in type 2 diabetes

  2004cited by this paper
• Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.

  2004cited by this paper
• Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

  2003cited by this paper
• Glucagon and regulation of glucose metabolism.

  2003cited by this paper
• Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

  2002cited by this paper
• Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis.

  2002cited by this paper
• Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists.

  2002cited by this paper
• Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists.

  2002cited by this paper
• Hepatic glucose production: therapeutic target in type 2 diabetes?

  2002cited by this paper
• Small-molecule glucagon receptor antagonists

  2002cited by this paper
• 1,2-Didehydro-3- and -4-(trifluoromethoxy)benzene: the \"aryne\" route to 1- and 2-(trifluoromethoxy)naphthalenes

  2001cited by this paper
• Development of potent truncated glucagon antagonists.

  2001cited by this paper
• Identification of alkylidene hydrazides as glucagon receptor antagonists.

  2001cited by this paper
• Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans

  2001cited by this paper
• New approaches in the treatment of type 2 diabetes.

  2000cited by this paper
• Cross-coupling of 1-aryl-5-bromopyrazoles: regioselective synthesis of 3,5-disubstituted 1-arylpyrazoles

  2000cited by this paper
• Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.

  2000cited by this paper
• Potent, orally absorbed glucagon receptor antagonists.

  1999cited by this paper
• Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

  1998cited by this paper
• 13C NMR study of the effects of leptin treatment on kinetics of hepatic intermediary metabolism.

  1998cited by this paper
• Alterations in Receptor Activation and Divalent Cation Activation of Agonist Binding by Deletion of Intracellular Domains of the Glucagon Receptor*

  1997cited by this paper
• Effects of III-IV linker mutations on human heart Na+ channel inactivation gating.

  1994cited by this paper
• Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats

  1994cited by this paper
• Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499].

  1994cited by this paper
• Catalytic asymmetric reductive amination of ketones via highly enantioselective hydrogenation of the CN double bond

  1994cited by this paper
• A Safe, Economical Method for the Preparation of ß-Oxo Esters

  1993cited by this paper
• CP-99,711: a non-peptide glucagon receptor antagonist

  1992cited by this paper
• The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM

  1988cited by this paper
• Calcium Channel Receptor Binding Studies for Diltiazem and Its Major Metabolites: Functional Correlation to Inhibition of Portal Vein Myogenic Activity

  1987cited by this paper
• Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist.

  1982cited by this paper
• The N-Alkylation and N-Arylation of Unsymmetrical Pyrazoles

  1979cited by this paper

• Coordination of Functional Oligonucleotides Yields a Versatile Nanocomposite Microneedle Patch to Facilitate Local Wound Microenvironment Remodeling via Systemic Hyperglycemia Regulation

  2025cites this paper
• Glucagon receptor family in GtoPdb v.2025.3

  2025cites this paper
• Nickel‐Catalyzed Cross Coupling of N‐Alkenyl Heterocycles and Aryl Sulfonium Salts: Expedient Access to N‐Benzyl Heterocycles

  2025cites this paper
• An updated patent review of small molecule glucagon receptor antagonists (2020–2024)

  2025cites this paper
• Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics

  2025cites this paper
• Iridium-Catalyzed Regio- and Enantioselective N-Allylation of Pyrazoles with Dienyl/Monoallylic Alcohols.

  2024cites this paper
• V1bR enhances glucose-stimulated insulin secretion by paracrine production of glucagon which activates GLP-1 receptor

  2024cites this paper
• The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures

  2024cites this paper
• G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery

  2024cites this paper
• A Review on Pyrazole Derivatives Used in the Treatment of Rheumatoid Arthritis: Recent Advancement and Drug Development.

  2024cites this paper
• Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor

  2023cites this paper
• VIP and PACAP receptors in GtoPdb v.2023.1

  2023cites this paper
• Ag2CO3 catalyzed aza-michael addition of pyrazoles to α, β-unsaturated carbonyl compounds: A new access to N-alkylated pyrazole derivatives

  2023cites this paper
• Glucagon 100 years. Important, but still enigmatic.

  2023cites this paper
• Enantioselective Synthesis of N-Benzylic Heterocycles by Ni/Photoredox Dual Catalysis.

  2022cites this paper
• Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes

  2022cites this paper
• Synthesis and anti‐diabetic activity of novel biphenylsulfonamides as glucagon receptor antagonists

  2021cites this paper
• Antiallergic drug Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist.

  2021cites this paper
• Glucagon receptor family in GtoPdb v.2021.3

  2021cites this paper
• Design, synthesis, biological evaluation, and molecular modeling studies of pyrazole-benzofuran hybrids as new α-glucosidase inhibitor

  2021cites this paper
• Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose

  2021cites this paper
• Design and synthesis of novel pyrazole-benzofuran hybrids: in vitro α-glucosidase inhibitory activity, kinetic and molecular modeling study

  2021cites this paper
• Allosteric modulators targeting GPCRs

  2020cites this paper
• Structural basis for allosteric modulation of class B GPCRs

  2020cites this paper
• Small molecule glucagon receptor antagonists: an updated patent review (2015–2019)

  2020cites this paper
• Structural Basis for Allosteric Modulation of Class B G Protein-Coupled Receptors.

  2020cites this paper
• TEMPORARY REMOVAL: Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure- based drug design.

  2019cites this paper
• Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP

  2019cites this paper
• FeCl3 /PVP as Green Homogeneous Catalyst to Synthesize 5-Amino-1H -Pyrazole-4-Carbonitriles from Malononitrile Derivatives

  2019cites this paper
• Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus

  2019cites this paper
• Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists.

  2019cites this paper
• Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.

  2019cites this paper
• Glucagon receptor family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• VIP and PACAP receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Enantioselective Synthesis of N-Benzylic Heterocycles: A Nickel and Photoredox Dual Catalysis Approach.

  2019cites this paper
• Regulation of glucose and lipid metabolism in health and disease

  2019cites this paper
• CPAA_A_202614 57..65

  2019cites this paper
• Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

  2019cites this paper
• Discovery of thiophene‐containing biaryl amide derivatives as novel glucagon receptor antagonists

  2018cites this paper
• Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review

  2018cites this paper
• Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.

  2018cites this paper
• Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

  2018cites this paper
• Design, synthesis, and effects of novel phenylpyrimidines as glucagon receptor antagonists.

  2018cites this paper
• A novel series of 4-methyl substituted pyrazole derivatives as potent glucagon receptor antagonists: Design, synthesis and evaluation of biological activities.

  2018cites this paper
• Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors)

  2018cites this paper
• Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs.

  2017cites this paper
• Extending the Structural View of Class B GPCRs.

  2017cites this paper
• Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators

  2017cites this paper
• DMT efficiently inhibits hepatic gluconeogenesis by regulating the Gαq signaling pathway.

  2017cites this paper
• Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes

  2017cites this paper
• Regio- and Enantioselective Rhodium-Catalyzed Addition of 1,3-Diketones to Allenes: Construction of Asymmetric Tertiary and Quaternary All Carbon Centers.

  2017cites this paper
• The New Biology and Pharmacology of Glucagon.

  2017cites this paper
• Novel approaches to treating type 2 diabetes

  2016cites this paper
• Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus

  2016cites this paper
• The therapeutic voyage of pyrazole and its analogs: A review.

  2016cites this paper
• Targeting hepatic glucose metabolism in the treatment of type 2 diabetes

  2016cites this paper
• Extra-helical binding site of a glucagon receptor antagonist

  2016cites this paper
• Glucagon actions on the kidney revisited: possible role in potassium homeostasis.

  2016cites this paper
• Brönsted acid-mediated annulations of 1-cyanocyclopropane-1-carboxylates with arylhydrazines: efficient strategy for the synthesis of 1,3,5-trisubstituted pyrazoles

  2016cites this paper
• Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.

  2016cites this paper
• Design, synthesis, structure-activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists.

  2016cites this paper
• Iron(III) phthalocyanine chloride-catalyzed oxidation–aromatization of α,β-unsaturated ketones with hydrazine hydrate: Synthesis of 3,5-disubstituted 1H-pyrazoles

  2016cites this paper
• Regioconvergent and Enantioselective Rhodium-Catalyzed Hydroamination of Internal and Terminal Alkynes: A Highly Flexible Access to Chiral Pyrazoles.

  2016cites this paper
• Regioselective Rhodium‐Catalyzed Addition of β‐Keto Esters, β‐Keto Amides, and 1,3‐Diketones to Internal Alkynes

  2016cites this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016cites this paper
• Recent progress in the development of small-molecule glucagon receptor antagonists.

  2015cites this paper
• Regio- and enantioselective synthesis of N-substituted pyrazoles by rhodium-catalyzed asymmetric addition to allenes.

  2015cites this paper
• Phase‐Transfer‐Catalyzed Asymmetric Synthesis of Chiral N‐Substituted Pyr­azoles by Aza‐Michael Reaction

  2015cites this paper
• Small molecule glucagon receptor antagonists: a patent review (2011 – 2014)

  2015cites this paper
• A novel series of indazole-/indole-based glucagon receptor antagonists.

  2015cites this paper
• Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.

  2015cites this paper
• Discontinued drug therapies to treat diabetes in 2014

  2015cites this paper
• Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity

  2015cites this paper
• Ligand-free Heck–Mizoroki reaction for 1,3,5-Trisubstituted Pyrazoles

  2015cites this paper
• Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure

  2015cites this paper
• Glucagon receptor antagonism induces increased cholesterol absorption[S]

  2015cites this paper
• Identification of a novel conformationally constrained glucagon receptor antagonist.

  2014cites this paper
• N-2-Hydroxybenzaldehyde acylhydrazone-Fe(III) complex: synthesis, crystal structure and its efficient and selective N-methylation.

  2014cites this paper
• Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus

  2014cites this paper
• The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.

  2014cites this paper
• Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.

  2014cites this paper
• G protein-coupled receptors as regulators of glucose homeostasis and therapeutic targets for diabetes mellitus.

  2014cites this paper
• desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.

  2013cites this paper
• An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases.

  2013cites this paper
• The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.

  2013cites this paper
• Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist

  2012cites this paper
• New avenues for the pharmacological management of type 2 diabetes: an update.

  2012cites this paper